Monday, February 01, 2021 12:31:40 AM
Pennsy,
I will correct you.
I hink some of those here have confused you.
MF never stated he would share data news at end of year.
That is over enthusiastic iHub boarders who are projecting their wishes upon other’s expectations.
He did state that they would hit initial data point by end of 2020.
In fact if you look at what MF says, he has been vague.
Why?
> they’re small, they have to play by the rules
> they are in constant contact with FDA,
> they’re protecting their patent application
But, you have to look beyond what Revive says.
He did acknowledge that 210 mark was enrolled by years end.
He just got more funding.
He hired a Thiol Donor Researcher.
Pharm-Olam has expanded sites.
The 1000 patient trial mark should be hit by February 1st, so I imagine data would come prior to the end of February. But we’ll see, because like everyone on here, it’s a best guess.
In fact right now, Only Pharm-Olam personnel probably know any results.
I will correct you.
I hink some of those here have confused you.
MF never stated he would share data news at end of year.
That is over enthusiastic iHub boarders who are projecting their wishes upon other’s expectations.
He did state that they would hit initial data point by end of 2020.
In fact if you look at what MF says, he has been vague.
Why?
> they’re small, they have to play by the rules
> they are in constant contact with FDA,
> they’re protecting their patent application
But, you have to look beyond what Revive says.
He did acknowledge that 210 mark was enrolled by years end.
He just got more funding.
He hired a Thiol Donor Researcher.
Pharm-Olam has expanded sites.
The 1000 patient trial mark should be hit by February 1st, so I imagine data would come prior to the end of February. But we’ll see, because like everyone on here, it’s a best guess.
In fact right now, Only Pharm-Olam personnel probably know any results.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
